Founded in 2020, Radiant Biotherapeutics is developing a next-generation antibody platform designed to overcome the limitations of conventional biologics. Using its proprietary Multabody™ technology, the company engineers single therapeutics capable of engaging multiple disease targets simultaneously, with the goal of delivering deeper, more durable responses across cancer, autoimmune, and infectious diseases.
From the beginning, Radiant was envisioned not just as a single-asset company, but as a platform capable of generating durable value by pairing scientific rigor with operational discipline. That ambition — and the path to realizing it — was shaped in close partnership with Amplitude Ventures.
From concept to company
Radiant’s origins trace back to a set of foundational scientific insights that highlighted both a significant therapeutic opportunity and a structural gap in the market. While the underlying biology had been explored in academic and early translational settings, it lacked a commercial framework capable of turning promise into practice. Amplitude recognized the promise of the platform that had been created by scientific founder, JP Julien, and started Radiant to in-license the intellectual property. In the early days, the Amplitude team was the entire founding team and drove the company through early proof of concept work, necessary to bring in other investors.
Amplitude played a central role in shaping Radiant from its earliest days, helping refine the company’s scientific focus and define its initial programs. Amplitude also assembled a leadership and advisory team aligned around execution. Bharat Srinivasa, Co-Founder and Principal at Amplitude Ventures, served as Radiant's founding CEO, and the team recruited industry veteran Jo Hulme as the company's Chief Scientific Officer. That hands-on approach laid the groundwork for a company built not only to advance compelling science, but also to navigate the realities of company building in today’s biotech environment.
“We landscaped the biologics market for close to 18 months, identifying gaps and charted where the next generation of antibody technologies would be pointed,” said Srinivasa. “Our projections perfectly lined up with the technology being developed at the Julien lab so we were able to quickly move to take the strong science from the bench into a clinical pipeline.”
An aligned financing partner
Amplitude led and participated in Radiant’s early financing, providing the capital needed to move decisively from formation into execution. More importantly, Amplitude brought a company-building mindset that influenced how Radiant prioritized programs, allocated resources, and planned for future growth.
“Radiant is exactly the kind of company we aim to build,” says Dion Madsen, Co-Founder and Partner at Amplitude Ventures. “It combines strong scientific foundations with a clear strategic thesis and leadership that understands how to translate complexity into focus. It was about building something meaningful and durable.”
As Radiant advanced, Amplitude worked closely with the team on everything from capitalization strategy and hiring plans to long-term portfolio positioning. That collaboration allowed Radiant to remain focused while retaining the flexibility needed to adapt as new data emerged.
New leadership for Radiant’s next phase of growth
In 2025, Amplitude helped recruit Deborah Geraghty as Radiant’s new President and CEO, marking an important inflection point in the company’s evolution. A seasoned biotech executive with deep experience advancing large-molecule therapeutics and scaling science-driven organizations, Geraghty was drawn to Radiant because of the strength of its platform and the nature of its investor partnership.
“What really stood out to me about Amplitude was their ability to see around corners,” says Geraghty. “They don’t just care about whether the science is interesting. They want to know that it can be translated into a real company that makes a real impact — and they engage deeply to help answer that question.”
She also points to Amplitude’s operating style as a differentiator. “They are thoughtful, prepared, and genuinely engaged, and not just at board meetings, but in the hard, in-between moments when critical decisions get made.”
Under Geraghty’s leadership, Radiant has continued to sharpen its strategy and build the internal capabilities required to advance its programs efficiently. Amplitude remains an active partner, providing strategic input while empowering the management team to lead.
“There’s a level of trust that Amplitude brings that is incredibly important,” Geraghty adds. “They challenge assumptions, but they do it in a way that’s constructive and grounded in a shared goal of building a great company.”
A true partnership
Radiant’s trajectory reflects the kind of partnership Amplitude seeks with all of its portfolio companies — one that extends well beyond financing. From company formation to leadership transition and execution, Amplitude has been deeply involved in helping Radiant navigate complexity, make disciplined choices, and stay focused on long-term value creation.
For Amplitude, Radiant exemplifies the firm’s approach to company building: identify differentiated science, assemble the right leadership, and remain actively engaged as a strategic partner. Meanwhile for Radiant, Amplitude has been a great partner, providing both the capital and conviction needed to pursue an ambitious vision.
As Radiant looks ahead to its next stage of growth, the company is well positioned to translate its scientific insights into meaningful outcomes for patients and investors alike.
